Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders

European Addiction Research

Volumn 13, Issue 4, 2007, Pages 230-243

  San, Luis ^a   Arranz, Belen ^a   Martinez Raga, Jose ^b  

^a HOSPITAL SAN RAFAEL   (Spain)

^b UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

Conventional antipsychotics; Dual diagnosis; Schizophrenia; Second generation antipsychotics; Substance use; Treatment outcome

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; METHADONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

CLINICAL TRIAL; COMORBIDITY; DATA BASE; DRUG EFFICACY; DRUG MECHANISM; EMBASE; HUMAN; MEDICAL RESEARCH; MEDLINE; PRIORITY JOURNAL; PSYCINFO; REVIEW; SCHIZOPHRENIA; SCISEARCH; SUBSTANCE ABUSE;

ALCOHOLISM; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MARIJUANA ABUSE; SCHIZOPHRENIA; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS;

EID: 34548661503     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104886     Document Type: Review

References (102)

1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-2518.
2. Thornicroft G: Cannabis and psychosis. Is there epidemiological evidence for and association? Br J Psychiatry 1990;157:25-33.
3. Abraham HD, Aldridge AM: Adverse consequences of lysergic acid diethylamide. Addiction 1993;88:1327-1334.
4. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG: The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112:141-148.
5. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller del D, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Liberman JA: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006;194:164-172.
6. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD: Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006;189:229-234.
7. Schimmelmann BG, Conus P, Schacht M, McGorry P, Lambert M: Predictors of service disengagement in first-admitted adolescents with psychosis. J Am Acad Child Adolesc Psychiatry 2006;45:990-999.
8. Semple DM, McIntosh AM, Lawrie SM: Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-194.
9. Degenhardt L, Hall W: Is cannabis use a contributory cause of psychosis? Can J Psychiatry 2006;51:556-565.
10. Soyka M, Albus M, Immler B, Kathmann N, Hippius H: Psychopathology in dual diagnosis and non-addicted schizophrenics - are there differences? Eur Arch Psychiatry Clin Neurosci 2001;251:232-238.
11. Mueser KT, Drake RE, Wallach MA: Dual diagnosis: a review of etiological theories. Addict Behav 1998;23:717-734.
12. Krystal JH, D'Souza DC, Madonick S, Petrakis IL: Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999;35:S35-S49.
13. Scheller-Gilkey G, Woolwine BJ, Cooper I, Gay O, Moynes KA, Miller AH: Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse 2003;29:553-566.
14. Potvin S, Pampoulova T, Mancini-Marie A, Lipp O, Bouchard RH, Stip E: Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006;77:796-798.
15. Blanchard JJ, Squires D, Henry T, Horan WP, Bogenschutz M, Lauriello J, Bustillo J: Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping. J Nerv Ment Dis 1999;187:72-79.
16. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A: Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006;29:409-416.
17. Chambers A, Krystal J, Self D: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83.
18. Green AI, Salomon MS, Brenner MJ, Rawlins K: Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Target CNS Neurol Disord 2002;1:129-139.
19. Tsuang JW, Eckman TE, Shaner A, Marder SR: Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry 1999;156:1119-1120.
20. Buckley PF: Novel antipsychotic medications and treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998;15:113-116.
21. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ: Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001;35:187-191.
22. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D: Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743-755.
23. Noordsy DL, Green AI: Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5:340-346.
24. Abou-Saleh MT: Psychopharmacology of substance misuse and comorbid psychiatric disorders. Acta Neuropsychiatrica 2004;16:19-25.
25. Ley A, Jeffery DP, McLaren S, Siegfried N: Treatment programmes for people with both severe mental illness and substance misuse (Cochrane Review); in The Cochrane Library, Issue 2. Oxford, Update Software, 2002.
26. Kosten TA: Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats. Schizophr Bull 1997;23:203-213.
27. Satel SL, Swann AC: Extrapyramidal symptoms and cocaine abuse. Am J Psychiatry 1993;150:347.
28. Wilkins JN: Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997;23:215-228.
29. Van Harten PN, Hoek HW, Kahn RS: Acute dystonia induced by drug treatment. BMJ 1999;319:623-626.
30. Bowers MB, Mazure CM, Nelson JC, Jatlow PI: Psychotogenic drug use and neuroleptic response. Schizophr Bull 1990;16:81-85.
31. Gerding LB, Labbate LA, Meason MO, Santos AB, Arana GW: Alcohol dependence and hospitalization in schizophrenia. Schizophr Res 1999;38:71-75.
32. McEvoy JP, Freudenreich O, Levin ED, Rose JE: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 1995;119:124-126.
33. King GR, Joyner C, Ellinwood EH: Continuous or intermittent cocaine administration: effects of flupenthixol treatment during withdrawal. Pharmacol Biochem Behav 1994;49:883-889.
34. Gawin FH, Allen D, Humblestone B: Outpatient treatment of 'crack' cocaine smoking with flupenthixol decanoate. A preliminary report. Arch Gen Psychiatry 1989;46:322-325.
35. Soyka M, De Vry J: Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence. Eur Neuropsychopharmacol 2000;10:325-332.
36. Soyka M, Sand P: Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry 1995;28:64-65.
37. Schilkrut R, Cabrera J, Morales E, Herrera L: Neuroleptics in the treatment of drug dependence in schizophrenics: a study with flupenthixol decanoate. Psychopharmacology 1988;96:342.
38. Levin FR, Evans SM, Coomaraswammy S, Collins ED, Regent N, Kleber HD: Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998;24:343-360.
39. Soyka M, Aichmuller C, von Bardeleben U, Beneke M, Glaser T, Hornung-Knobel S, Wegner U: Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res 2003;9:65-72.
40. Rubio G, Casas M: Treatment of schizophrenia in subjects with SUD: a review. Actas Esp Psiquiatr 2001;29:124-130.
41. Yovell Y, Opler LA: Clozapine reverse cocaine craving in a treatment-resistant mentally ill chemical abuse: a case report and a hypothesis. J Nerv Ment Dis 1994;182:591-592.
42. Albanese MJ, Khantzian EJ, Murphy SI, Green AI: Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994;151:780-781.
43. Lee ML, Dickson RA, Campbell M, Oliphant J, Gretton H, Dalby JT: Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998;43:855-856.
44. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI: Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000;20:94-98.
45. Drake RE, Xie H, McHugo GI, Green AI: The effects of clozapine on alcohol and drug use disorder among patients with schizophrenia. Schizophr Bull 2000;26:441-449.
46. Buckley P, Thompson P, Way L, Meltzer HY: Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151:385-389.
47. Buckley P, Thompson PA, Way L, Meltzer HY: Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55:114-116.
48. Volavka J: The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry 1999;60:43-46.
49. Kelly DL, Gale EA, Conley RR: Clozapine treatment in patients with prior substance abuse. Can J Psychiatry 2003;48:111-114.
50. Marcus P, Snyder R: Reduction of comorbid substance abuse with clozapine. Am J Psychiatry 1995;152:959.
51. McEvoy J, Freudenreich O, McGree M, VanderZwaag C, Levin E, Rose J: Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995;37:550-552.
52. George TP, Sernyak MJ, Ziedonis DM, Woods SW: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995;56:344-346.
53. McEvoy JP, Freudenreich O, Wilson WH: Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125-129.
54. Green AI, Zimmet SV, Strous RD, Schildkraut JJ: Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999;6:287-296.
55. Kerwin R, Taylor D: New antipsychotics. A review of their current status and clinical potential. CNS Drugs 1996;6:71-82.
56. Wagstaff AJ, Bryson HM: Clozapine. A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995;4:370-400.
57. Perry PJ: Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 2001;35:19-29.
58. Bhana N, Foster RH, Olney R, Plosker GL: Olanzapine. An updated review of its use in the treatment of schizophrenia. Drugs 2001;61:111-161.
59. Glazer WM: Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 1997;58:18-21.
60. Baño MD, Mico JA, Agujetas M, Lopez ML, Guillen JL: Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels. Actas Esp Psiquiatr 2001;29:215-220.
61. Longo LP: Olanzapine for cocaine craving and relapse prevention in two patients. J Clin Psychiatry 2002;63:595-596.
62. Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG: Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21:217-221.
63. Noordsy DL, O'Keefe C: Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999;60:47-51.
64. Noordsy DL, O'Keefe C, Mueser KT, Xie H: Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001;52:501-507.
65. Sattar SP, Bhatia SC: Olanzapine for cocaine craving and relapse prevention. J Clin Psychiatry 2003;64:969.
66. Tsuang J, Marder SR, Han A, Hsieh W: Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 2002;63:1180-1181.
67. Smelson DA, Ziedonis D, Williams J, Losonczy M, Williams J, Steinberg ML, Kaune M: The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence. J Clin Psychopharmacol 2006;26:9-12.
68. Conley RR, Kelly DL, Gale EA: Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33:95-101.
69. Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C, Caroff SN: Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005;193:379-386.
70. Albanese MJ: Safety and efficacy of risperidone in substance abusers with psychosis. Am J Addict 2001;10:190-191.
71. Tsuang JW, Eckman TE, Marder SR, Tucker D: Can risperidone reduce cocaine use in substance abusing schizophrenic patients. J Clin Psychopharmacol 2002;22:629-630.
72. Huang CC: Risperdal reduces alcohol use in dual disabled schizophrenia patients. Eur Neuropsychopharmacol 1996;6:43.
73. Casas M, Gutiérrez M, Gibert J, Bobes J, Roncero C, Octavio I: Risperidona en el tratamiento de pacientes psicóticos con abuso y dependencia de opiáceos. Actas Esp Psiquiatr 2001;29:380-385.
74. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D: Risperidone decrease craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002;47:671-675.
75. Poling J, Kosten T: Risperidone for substance-dependent psychotic patients. Addict Disord Their Treatment 2005;4:1-3.
76. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Muñoz F, Alamo C: Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51:531-539.
77. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD: Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 2003;60:81-85.
78. Adityanjee Schulz SC: Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002;63:32-38.
79. Brown ES, Nejtek VA, Perantie DC, Bobadilla L: Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406-411.
80. Potvin S, Stip E, Roy JY: The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 2004;49:711.
81. Weisman RL: Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003;33:85-89.
82. Cahill CA: Effective treatment with quetiapine in a patient with schizoaffective disorder and polysubstance dependence. Prim Psychiatry 2004;11:46-47.
83. Brown ES, Nejtek VA, Perantie DC, Rajan TN, Rush AJ: Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 2003;23:384-388.
84. Ohlsen RI, Pilowsky LS: The partial agonism in psychiatry: recent developments. J Psychopharmacol 2005;19:408-413.
85. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF: Aripiprazole in schizophrenia with cocaine dependence. A pilot study. J Clin Psychopharmacol 2005;25:363-366.
86. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L: Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66:756-760.
87. Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
88. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589.
89. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
90. Davis JM, Chen N: Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry 2005;20:7-14.
91. Hamann J, Leucht S, Kissling W: Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003;36:18-26.
92. Potvin S, Stip E, Roy JY: Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypothesis. Int Clin Psychopharmacol 2003;18:121-132.
93. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255.
94. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
95. Soyka M, Winter C, Kagerer S, Brunnauer M, Laux G, Möller HJ: Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J Psychiatr Res 2005;39:101-108.
96. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712.
97. Müller U, Werheid K, Hammerstein E, Jungmann Becker T: Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics. Eur Psychiatry 2005;20:70-73.
98. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842.
99. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132.
100. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA: Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005;72:249-258.
101. Brunette MF, Mueser KT: Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. J Clin Psychiatry 2006;67:10-17.
102. Kavanagh DJ, Young R, White A, et al: A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev 2004;23:151-155.